To treat KRAS-driven Cancers
Boehringer lngelheim and Lupin announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
